TrialThe Lancet. Oncology2020

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Robert H Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.